Abstract
Inhibition of telomerase is an exciting therapeutic target, since it is required for the long-term proliferation of most cancer cells but not present in most somatic cells. However, effective telomerase inhibitors have yet to be tested in clinical trials. In this issue of Cancer Cell, Seimiya and coworkers (Seimiya et al., 2005) explore inhibiting tankyrase, an enzyme involved in making telomeres accessible to telomerase. Adding a partial inhibition of tankyrase to a partial inhibition of telomerase drove cancer cells into crisis and death. The combination of tankyrase and telomerase inhibitors may offer new opportunities for realizing the promise of telomerase inhibition therapy.
| Original language | English (US) |
|---|---|
| Pages (from-to) | 1-2 |
| Number of pages | 2 |
| Journal | Cancer Cell |
| Volume | 7 |
| Issue number | 1 |
| DOIs | |
| State | Published - Jan 2005 |
Fingerprint
ASJC Scopus subject areas
- Cancer Research
- Cell Biology
- Oncology
Cite this
Mechanism-based combination telomerase inhibition therapy. / Shay, Jerry W.; Wright, Woodring E.
In: Cancer Cell, Vol. 7, No. 1, 01.2005, p. 1-2.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Mechanism-based combination telomerase inhibition therapy
AU - Shay, Jerry W.
AU - Wright, Woodring E.
PY - 2005/1
Y1 - 2005/1
N2 - Inhibition of telomerase is an exciting therapeutic target, since it is required for the long-term proliferation of most cancer cells but not present in most somatic cells. However, effective telomerase inhibitors have yet to be tested in clinical trials. In this issue of Cancer Cell, Seimiya and coworkers (Seimiya et al., 2005) explore inhibiting tankyrase, an enzyme involved in making telomeres accessible to telomerase. Adding a partial inhibition of tankyrase to a partial inhibition of telomerase drove cancer cells into crisis and death. The combination of tankyrase and telomerase inhibitors may offer new opportunities for realizing the promise of telomerase inhibition therapy.
AB - Inhibition of telomerase is an exciting therapeutic target, since it is required for the long-term proliferation of most cancer cells but not present in most somatic cells. However, effective telomerase inhibitors have yet to be tested in clinical trials. In this issue of Cancer Cell, Seimiya and coworkers (Seimiya et al., 2005) explore inhibiting tankyrase, an enzyme involved in making telomeres accessible to telomerase. Adding a partial inhibition of tankyrase to a partial inhibition of telomerase drove cancer cells into crisis and death. The combination of tankyrase and telomerase inhibitors may offer new opportunities for realizing the promise of telomerase inhibition therapy.
UR - http://www.scopus.com/inward/record.url?scp=12344288452&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=12344288452&partnerID=8YFLogxK
U2 - 10.1016/j.ccr.2004.12.012
DO - 10.1016/j.ccr.2004.12.012
M3 - Article
C2 - 15652743
AN - SCOPUS:12344288452
VL - 7
SP - 1
EP - 2
JO - Cancer Cell
JF - Cancer Cell
SN - 1535-6108
IS - 1
ER -